# US 2016/0256398 A1 · Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256398 A1
- Document ID: US20160256398A1
- Status: Published application
- Kind: A1
- Application number: 14/886,333
- Filed: 2015-10-19
- Published: 2016-09-08
- Earliest claimed: 2009-08-24
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: Astrid-Maria Hojer; Pernille Gundorf Drewes; Jens Kateb
- Web page: https://patentgrep.com/patent/US20160256398A1

## CPC

- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5078: {with drug-free core}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof adapted so that release does not take place in the stomach is provided.

## Claims

### Claim 1

A pharmaceutical composition for oral administration, comprising Compound I or a pharmaceutically acceptable acid addition salt thereof,
wherein Compound I is 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and the composition is adapted so that said compound is not released in the stomach.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is a sustained release composition.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition is a delayed release composition.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the composition comprises a pH-sensitive coating.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the composition is an enteric coated tablet.

### Claim 6 (depends on 4)

The composition of claim 4, wherein the composition is a multiparticulate composition in which substantially each particle is enteric coated.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition is a tablet comprising Compound I or a pharmaceutically acceptable acid addition salt thereof, mannitiol, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose and magnesium stearate, which tablet is coated with methacrylic acid ethyl acrylate (1:1) copolymer.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition comprises Compound I HBr.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition comprises 1-50 mg of Compound I HBr.

### Claim 10 (depends on 1)

A method of treating a disease selected from mood disorders; major depressive disorder; general anxiety disorder; panic disorder; post traumatic stress disorder; depression associated with cognitive impairments, Alzheimer's disease or anxiety; depression with residual symptoms; chronic pain; eating disorder or abuse, the method comprising the administration of a therapeutically effective amount of the pharmaceutical composition of claim 1 to a patient in need thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is a sustained release composition.

### Claim 12 (depends on 10)

The method of claim 10, wherein the composition is a delayed release composition.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition comprises a pH sensitive coating.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition is an enteric coated tablet.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition is a multiparticulate composition in which each particle is enteric coated.

### Claim 16 (depends on 10)

The method of claim 10, wherein the composition is a tablet comprising Compound I or a pharmaceutically acceptable acid addition salt thereof, mannitiol, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose and magnesium stearate, which tablet is coated with methacrylic acid ethyl acrylate (1:1) copolymer.

### Claim 17 (depends on 10)

The method of claim 10, wherein the composition comprises Compound I HBr.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition comprises 1-50 mg of Compound I HBr.
